

## PRESS RELEASE

---

# Camurus to present Interim report January-March 2019 on 9 May

**Lund, Sweden — 7 May 2019** — Camurus (NASDAQ STO: CAMX) today announced that the Company will release its interim report January-March 2019 on 9 May at 1:00 pm CET. The report will be available on the Company's web site at [www.camurus.com](http://www.camurus.com).

Fredrik Tiberg, President and CEO, and key members of the management team, will present the results and address questions from investors, analysts and media on 9 May at 2:00 pm CET. An audiocast to the presentation will be available at:

<https://financialhearings.com/event/12052>

The presentation material will be available on the company website shortly before the event.

### **About Camurus**

*Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus' clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit [www.camurus.com](http://www.camurus.com).*

### **For more information**

Fredrik Tiberg, President & CEO

Tel. +46 (0)46 286 46 92

[fredrik.tiberg@camurus.com](mailto:fredrik.tiberg@camurus.com)

Fredrik Joabsson, Chief Business Development Officer

Tel. +46 (0)70 776 17 37

[ir@camurus.com](mailto:ir@camurus.com)

This information was submitted for publication at 04.00 pm CET on 7 May 2019.